REG - AstraZeneca PLC - ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

01/11/2017 07:06

RNS Number : 2163V
AstraZeneca PLC
01 November 2017
1 November 2017 07:00 GMT
ASTRAZENECA AND ASPEN COMPLETE AGREEMENT FOR
RESIDUAL RIGHTS TO ANAESTHETIC MEDICINES
AstraZeneca today announced that it has completed the commercialisation agreement(announced 14 September 2017) with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan, EMLA,Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
AstraZeneca initially entered anagreementwith AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US. Under the terms of the new agreement, AGI has now acquired the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations


Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Matt Kent
UK/Global
+44 203 749 5906
Gonzalo Via
UK/Global
+44 203 749 5916
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677



Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Christer Gruvris
Diabetes; Autoimmunity, Neuroscience & Infection
+44 203 749 5711
Nick Stone
Respiratory; Brilinta
+44 203 749 5716
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCFSSSWFFWSESF